Found 20 articles for: "JAK"
Successful Treatment of Dystrophic Epidermolysis Bullosa With the JAK1 Inhibitor Abrocitinib
April 2026 | Volume 25 | Issue 4 | Case Reports | 384 | Copyright © April 2026
Introduction: JAK inhibitors are increasingly being utilized for the treatment of diseases beyond their nonclassical indications, and thehighly selective JAK1 inhibi...
Read MoreRacial and Ethnic Representation in Clinical Trials of Janus Kinase Inhibitors for Dermatologic Conditions: A Systematic Review
April 2026 | Volume 25 | Issue 4 | Original Article | 316 | Copyright © April 2026
Background: Janus kinase (JAK) inhibitors represent promising therapies for dermatologic conditions, including psoriasis, hidradenitis suppurativa (HS), atopic dermatitis (AD), s...
Read MoreDelays in Medical Care Among Skin of Color Melanoma Patients: A Population-Based Study
April 2026 | Volume 25 | Issue 4 | Features | 391 | Copyright © April 2026
Association Between Topical Ruxolitinib Treatment and Psychiatric Outcomes in Adults With Vitiligo
April 2026 | Volume 25 | Issue 4 | Features | 388 | Copyright © April 2026
Efficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata
March 2026 | Volume 25 | Issue 3 | Original Article | 204 | Copyright © March 2026
Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss on the scalp and body, leading to a reduced quality of life and psychosocial burden for patients. The only US ...
Read MoreExpert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand Eczema
March 2026 | Volume 25 | Issue 3 | Original Article | 228 | Copyright © March 2026
Background: Chronic hand eczema (CHE) is a common, heterogeneous inflammatory skin disease associated with substantial symptom burden, impaired hand function, reduced quality of ...
Read MoreBaricitinib-Related Adverse Events in Alopecia Areata and Rheumatoid Arthritis: A Comparative Study
March 2026 | Volume 25 | Issue 3 | Features | 286 | Copyright © March 2026
Treatment of Generalized Granuloma Annulare With Biologics and Oral JAK Inhibitors: A Case Series
February 2026 | Volume 25 | Issue 2 | Features | e26 | Copyright © February 2026
Treatment of Refractory Pruritic Dermatitis in the Setting of Primary Biliary Cholangitis and CREST Syndrome With Upadacitinib
November 2025 | Volume 24 | Issue 11 | Case Reports | 1138 | Copyright © November 2025
Primary biliary cholangitis (PBC) can present with overlapping features of limited systemic sclerosis, commonly known as calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, a...
Read MoreManagement of Hailey-Hailey Disease With Ruxolitinib 1.5% Cream
November 2025 | Volume 24 | Issue 11 | Case Reports | 1141 | Copyright © November 2025
Introduction: Benign Familial Pemphigus (Hailey-Hailey Disease [HHD]) is a rare chronic condition, with treatments focusing on managing disease symptoms.Case...
Read MoreRuxolitinib Cream Versus Triamcinolone Cream in Adults With Mild to Moderate Atopic Dermatitis
October 2025 | Volume 24 | Issue 10 | Original Article | 1036 | Copyright © October 2025
Atopic dermatitis (AD), a chronic inflammatory skin disease, is typically treated with topical corticosteroids in patients with mild to moderate disease, creating an ongoing need for nonsteroidal...
Read MoreThe Role of Simultaneous Janus Kinase Inhibitor and Biologic Therapy Use for Refractory Atopic Dermatitis
October 2025 | Volume 24 | Issue 10 | Case Reports | 1043 | Copyright © October 2025
Post-COVID-19 Alopecia Universalis: Autoimmune Hair Loss and the Challenge of Relapse Management
September 2025 | Volume 24 | Issue 9 | Case Reports | 938 | Copyright © September 2025
Background: Alopecia universalis (AU) is the most severe form of alopecia areata (AA), characterized by complete scalp and body hair loss. While post-COVID-19 hair loss is often ...
Read MoreThe Use of Biologic Therapeutic Regimens in Cutaneous and Systemic Mastocytosis: A Scoping Review
July 2025 | Volume 24 | Issue 7 | Original Article | 687 | Copyright © July 2025
Background: Mastocytoses, a category of diseases characterized by the clonal proliferation of mast cells and the release of their mediators, can be broadly classified as systemic...
Read MoreIs Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis
May 2025 | Volume 24 | Issue 5 | Original Article | 530 | Copyright © May 2025
Background: Atopic dermatitis (AD) is a chronic inflammatory skin condition associated with risk of cardiovascular disease (CVD), potentially mediated by persistent systemic infl...
Read MoreAlopecia Universalis: Never Give Up?
March 2025 | Volume 24 | Issue 3 | Case Reports | 316 | Copyright © March 2025
Introduction: Oral Janus kinase inhibitors (JAKi) have demonstrated significant promise in hair regrowth for severe alopecia areata. Baricitinib and ritlecitinib are two medicati...
Read MoreThe Role of JAK Inhibitors in the Treatment of Cutaneous Lupus Erythematosus: A Review
December 2024 | Volume 23 | Issue 12 | Original Article | 1100 | Copyright © December 2024
Cutaneous lupus erythematosus (CLE), a manifestation of the chronic autoimmune disease lupus erythematosus (LE), showcases diverse clinical, immunologic, and histologic attributes. CLE can be fur...
Read MoreThe ABCs of JAKis: A Clinician's Guide to Safety and Monitoring of the Systemic JAK Inhibitors
October 2024 | Volume 23 | Issue 10 | Original Article | 852 | Copyright © October 2024
Janus kinase inhibitors (JAKis) have recently emerged in the arsenal of tools to treat dermatological conditions. However, there are some concerns regarding these treatments due to their boxed wa...
Read MoreAnalysis of Reddit Reveals JAK Inhibitor Questions Among Atopic Dermatitis Patients
April 2024 | Volume 23 | Issue 4 | Editorials | e121 | Copyright © April 2024
Reddit is a popular social media website that is increasingly being used as a source of health information and discussion, especially among the younger population. We analyzed the subreddit "ecze...
Read MoreJAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies
December 2022 | Volume 21 | Issue 12 | Original Article | 1298 | Copyright © December 2022
Dermatologists treating atopic dermatitis are interested in the safety profile of the recently available JAK inhibitors, upadacitinib and abrocitinib, especially after they received boxed safety warni...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
